Mural Oncology plc (Nasdaq: MURA) announced its financial results for the second quarter of 2025, reporting a net loss of $48.0 million, a notable increase from the $31.6 million net loss recorded in the same period in 2024. This increase was primarily due to $17.5 million in restructuring and impairment charges related to severance, lab equipment impairment, and the termination of research and development programs. As of June 30, 2025, Mural Oncology's cash and cash equivalents stood at $77.1 million. The company has provided guidance estimating cash and cash equivalents of approximately $43 million to $48 million by December 31, 2025, assuming no consummation of a transaction or strategic alternative by year-end. In a significant business update, Mural Oncology announced the discontinuation of all clinical development of its lead product candidate, nemvaleukin alfa, and the exploration of strategic alternatives to maximize shareholder value. This move includes a 90% reduction in workforce and the termination of other research and development activities, including IL-18 and IL-12 programs. The company continues to explore strategic alternatives, but there is no assurance of a transaction or acquisition being completed.